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Abstract  11 
 12 
The encapsulation of eugenol (E) by spray-drying using whey protein (WP) or soy lecithin (LE) 13 
and maltodextrin in combination with oleic acid (OA) and chitosan (CH) was analysed in order 14 
to obtain antioxidant and antimicrobial powders for food applications. Formulations with only 15 
WP or LE showed higher encapsulation efficiencies (EE) (95-98%) and antibacterial effect against 16 
E. coli and L. innocua due to their greater E load. Incorporation of OA or CH promoted lower EE, 17 
which negatively affected the antimicrobial and antioxidant activities of the powders. 18 
Furthermore, the addition of CH implied less thermal protection against the E losses. The 19 
eugenol release was not notably affected by pH or polarity of the food simulant, but the release 20 
rate significantly decreased when incorporating OA and CH. The E-LE formulations better 21 
retained the eugenol than E-WP powders when heated above 200 ᵒC, this being relevant for the 22 
powder inclusion in thermally treated products. 23 
 24 
Keywords: encapsulation efficiency, release kinetics, oleic acid, chitosan, antioxidant capacity, 25 
antibacterial properties. 26 
1. Introduction 27 
 28 
Over the last few years, substantial efforts have been focused on making use of natural 29 
compounds to develop novel health-promoting ingredients for use in the food industry. In this 30 
sense, increasing interest has been shown in the extracts from aromatic plants, such as essential 31 
oils, due to their antioxidant and antimicrobial properties (Prakash, Kedia, Mishra & Dubey, 32 
2015). Eugenol (E) is a natural phenolic substance found as a major compound in different plant 33 
essential oils, such as clove, nutmeg, cinnamon or basil (Chatterjee & Bhattacharjee, 2013). 34 
Particular antimicrobial activity for E has been described by different authors against Gram 35 
positive and Gram negative bacteria (Bacillus subtilis, Clostridium sporogenes, Enterococcus 36 
faecalis, Lactobacillus plantarum, Listeria monocytogenes, Escherichia coli and Salmonella 37 
pullorum, (Dorman & Deans, 2000)), fungi (Aspergillus carbonarius and Penicillium roqueforti 38 
(Šimović, Delaš, Gradvol, Kocevski & Pavlović, 2014)) and yeast (Saccharomyces cerevisiae and 39 
Candida (Pinto, Vale-Silva, Cavaleiro & Salgueiro, 2009)). Its effective antioxidant capacity has 40 
also been studied by several authors (Kamatou, Vermaak & Viljoen, 2012; Ogata, Hoshi, Urano 41 
& Endo, 2000). Chatterjee & Bhattacharjee (2015) successfully incorporated eugenol-rich clove 42 
extract in mayonnaise as a flavoring agent and as a source of natural antioxidants to improve its 43 
shelf-life and functional value. Cortes-Rojas, Souzca & Oliveira (2014) also produced antioxidant 44 
powder products with solid lipid nanoparticles (SLN) containing eugenol. 45 
Nevertheless, the beneficial properties of eugenol can be reduced by inadequate storage 46 
conditions (Fang & Bhandari, 2010) due to their volatility and sensitivity to oxygen, light or heat 47 
(Shao et al., 2018). Moreover, its incorporation into aqueous systems, such as most foods, is 48 
limited by its low water solubility and impact on flavor (Choi, Soottitantawat, Nuchucha, Min & 49 
Ruktanonchai, 2009). Most of these problems can be overcome by using encapsulation 50 
techniques, allowing for the easier handling of the active compound, a better protection during 51 
storage and transportation and a better control in the release (Bae & Lee, 2008). Spray drying is 52 
one of the most widely used technique in encapsulation, being economical and the most feasible 53 
from the industrial point of view. Nevertheless, the composition of the aqueous phase must be 54 
optimized in order to ensure the formation of a good shell material, entrapping the active 55 
compound in the core, after the drying process; this allows for its controlled release when the 56 
powder is incorporated into a determined matrix. Spray drying has been extensively used for 57 
the encapsulation of different bioactive ingredients, including vitamins, polyunsaturated oils, 58 
phenolic compounds, enzymes, probiotics or some other compounds with an undesirable flavor, 59 
for masking purposes (Augustin & Hemar, 2009). The effectiveness of the encapsulation process 60 
is greatly affected by the properties/stability of the initial dispersion/emulsion of the active 61 
compound and, consequently, by the wall materials used in their formulation (Bae et al., 2008; 62 
Ré, 1998; Shao et al., 2018). In addition to the encapsulating efficiency, the antimicrobial or 63 
antioxidant properties of the encapsulated compound in the final dried capsules is affected by 64 
its total load in the powder (active/support compounds ratio) and its release kinetics into a 65 
determined target medium into which it could be incorporated. All these factors define the 66 
effective concentration on the target point, which must be studied to ensure the required 67 
functionality.  68 
The components of encapsulation matrices for food application purposes are limited to edible, 69 
preferably inexpensive, materials, biopolymers being the ideal candidates meeting these 70 
requirements. Proteins, polysaccharides and polar lipids such as lecithin have been proposed as 71 
promising vehicles for the protection and/or delivery of bioactive ingredients.  Proteins, such as 72 
whey protein are usually incorporated to promote emulsion formation and interfacial 73 
stabilization in the capsule-forming dispersions. The chemical structure of lecithin allows for the 74 
formation of liposomes which can entrap different kinds (more or less polar) of active 75 
compounds (Liolios, Gortzi, Lalas, Tsaknis & Chinou, 2009). At neutral pH, phosphate and 76 
carbonyl groups from phosphatidylcholine and phosphatidylethanolamine components in 77 
lecithin contribute to the negative charge of the particles in the emulsion, thus contributing to 78 
emulsion stability by charge (Dickinson, 1993). Polysaccharides can act as stabilizers by 79 
increasing the viscosity of the continuous phase or by means of the development of electrostatic 80 
interactions at the oil-water interface. In this sense, positively charged chitosan molecules in 81 
acid media could enhance the stability of the dispersion by means of a viscous electro-steric 82 
effect at the interface, thus promoting dispersion stability (Rodríguez, Albertengo & Agullo, 83 
2002). Maltodextrins can improve the properties of the capsules during the drying stage due to 84 
the formation of a larger crust around the drops, thus providing good protection against 85 
oxidation (Sheu & Rosenberg, 1998). Whey protein isolate (WP) or LE together with MD could 86 
form good wall systems able to stabilise in oil droplets in the oil-water emulsions, favouring the 87 
formation microcapsules during the emulsion spray drying (Karadag, Özçelik, Sramek, Gibis, 88 
Kohlus, Weiss, 2013). 89 
On the other hand, the use of lipophilic carriers (such as oleic acid) to favor the dispersion of 90 
poorly water-soluble lipid active agents or to favor its retention after processing have reported 91 
by several authors (Woo, Mirsan, Lee & Tan, 2014; Perdones, Vargas, Atarés & Chiralt, 2014).   92 
The aim of this study was to encapsulate eugenol by spray drying using WP or LE as wall-93 
materials and to characterize the different formulations before (emulsion properties) and after 94 
drying, in terms of the encapsulation efficiency, thermal stability, release kinetics and 95 
antioxidant and antimicrobial activities. The effect of the incorporation of both oleic acid (OA), 96 
as eugenol carrier, and chitosan (CH), as a potential stabilizer, on the properties of the 97 
encapsulating systems was analysed. 98 
 99 
 100 
2. Material and Methods 101 
 102 
2.1. Raw materials 103 
 104 
Soy lecithin (LE) Lipoid S45 from Lipoid GmbH (batch 574510, Ludwigshafen, Germany); whey 105 
protein isolate (WP) Prodiet 90S (95% whey and 1.5% fat)  from Ingredia (batch 131848, France); 106 
maltodextrin (MD) Kyrosan E18 1910 QS (DE19.2, batch 02157372, Emsland Group, Germany); 107 
purified oleic acid (OA) (77% C18:1; 11% C18:2; 4% C16:0; 1% C16:1; 3% C18:0) from VWR 108 
Chemicals (Germany) and high molecular weight chitosan (CH) from Sigma-Aldrich (Madrid, 109 
Spain) were used to encapsulate pure eugenol (E), also from Sigma-Aldrich (batch STBD6235V, 110 
Madrid, Spain). 111 
Sodium hydroxide (Merck, Darmstadt, Germany), boron trifluoride in methanol and sodium 112 
chloride (Sigma–Aldrich, Steinheim, Germany), sodium sulphate (purity 99%, VWR International, 113 
West Chester, PA, USA), C19:0 methyl ester and a GLC-63 mixture of fatty acid methyl esters 114 
(Nu-Check Prep, Elysian, MN, USA) as reagents and heptane and 2-propanol (Rathburn 115 
Chemicals Ltd., Walkerburn, Scotland) as HPLC grade solvents were used for the 116 
chromatographic fatty acid analysis. Glacial acetic acid, absolute ethanol and methanol and 117 
diphosphorus pentoxide (P2O5) were purchased from Panreac AppliChem (Barcelona, Spain) and 118 
2,2-Diphenyl-1-pikryl-hydrazyl and Folin-Ciocalteu reagent were obtained from Sigma-Aldrich 119 
(Madrid, Spain), in order to determine the other assays. 120 
 121 
2.2. Emulsion preparation 122 
 123 
Whey Protein Isolate (WP) or Lecithin (LE) were mixed with Maltodextrin in a WP/LE:MD ratio 124 
of 1:42 (w/w) to obtain aqueous dispersions (43g solids/100g). After leaving these aqueous 125 
solutions overnight under stirring, 3% eugenol (w/w) was added, obtaining the formulations E-126 
WP and E-LE (Table S1). 7 wt. % of oleic acid was added in formulations EOA-WP, EOA-LE, EOA-127 
WPCH and EOA-LECH (Table S1). All of the dispersions were homogenized with a Rotor Stator 128 
(Ultra-Turrax T 25 Basic, IKA Werke GmbH & Co. KG, Germany) at 11,000 rpm for 6 minutes and 129 
microfluidized (three cycles) with the high-pressure homogenizer (Microfluidics M-110Y, 130 
Newton, Massachusetts, USA) at 15,000 psi pressure (103,42 MPa). Formulations with CH (EOA-131 
WPCH and EOA-LECH) were obtained by previously dispersing 1% (w/w) chitosan (CH) in 1% (v/v) 132 
acetic acid solution for 14 h, under stirring at 150 rpm. The chitosan solution was added to 133 
formulations in a CH solution:emulsion ratio of 1.5:10. 134 
 135 
2.3. Spray-drying  136 
 137 
All of the emulsions were spray dried by a Mobile Minor TM spray-dryer (GEA Niro, GEA Process 138 
Engineering A/S, Søborg, Denmark) with a two-fluid atomizer (co-current two-fluid nozzle 139 
system). Samples were introduced into the drying chamber at an initial flow rate of 20 mL/min 140 
and an inlet air temperature adjusted to 180 °C. The outlet temperature was kept at 80 ± 2 °C 141 
by controlling the feed rate using a peristaltic pump (Watson Marlow 520s IP31, head type 314, 142 
Watson-Marlow Bredel Pumps, Cornwall, UK). During spray-drying the fan speed was set to 143 
2,800 rpm and the atomization air flow pressure, 1.9 bar. After spray-drying, powders were 144 
vacuum-packaged in polypropylene bags and stored under refrigeration and dark conditions 145 
until further analysis were carried out. 146 
 147 
2.4. Characterization of the emulsions 148 
 149 
2.4.1. Z-potential 150 
 151 
The Z-Potential of the emulsions was measured in triplicate by using a dynamic light scattering 152 
instrument capable of measuring electrophoretic mobility (Zetasizer nano ZS, Malvern 153 
Instruments, Worcestershire, UK). The E-LE formulation was measured without dilution. The rest 154 
of the emulsions were diluted to reach a final concentration of 1% (w/w) to prevent multiple 155 
scattering effects. 156 
 157 
2.4.2. Particle size  158 
 159 
The technique of laser diffraction was used to determine the size of particles in emulsions 160 
(Mastersizer 3000, Malvern Instruments). The Mie theory was applied by considering refractive 161 
and absorption indexes of 1.48 and 0.01, respectively. Samples were diluted in de-ionised water 162 
at 2500 rpm until an obscuration rate of 10% was obtained. D32 (surface weighted mean 163 
diameter) and D43 (volume weighted mean diameter) parameters were obtained. Light 164 
microscopy images of the emulsions were taken using a light microscope (Olympus, GWB MTV-165 
3, Japan) with a digital camera. 166 
 167 
2.4.3. Rheological behaviour 168 
 169 
The rheological behaviour of emulsions by six-fold at 20°C were characterized. The flow curves 170 
(apparent viscosity as a function of shear rate) of emulsions were determined by ThermoHaake 171 
Rheostress 600 rheometer (Thermo Electron GmbH, Dreieich, Germany) equipped with rotating 172 
cone of 35 mm in diameter and cone angle of 1°, over a shear rate range of 0.03–100–0.03 s−1. 173 
Ostwald model was fitted to the flow curves. 174 
 175 
2.5. Characterization of the spray-dried powders 176 
 177 
2.5.1. Particle size and microstructure (SEM) 178 
 179 
The particle size of the spray-dried powder formulations was measured by the laser diffraction 180 
technique (Mastersizer 3000, Malvern Instruments, UK), equipped with a dry dispersion unit. A 181 
refractive index of 1.48 and an absorption of 0.01 was also considered. Samples were fed into 182 
the system at a feed rate of 60% and a pressure of 2.2 bar until an obscuration rate was obtained 183 
within the range of 0.5-6%. The parameters, D3.2 and D4,3, were obtained.  184 
The microstructure of the microcapsules was evaluated by means of scanning electron 185 
microscopy (SEM) (JEOL, JSM-5410, Japan). The powders were previously conditioned in a 186 
desiccator with diphosphorus pentoxide (P2O5) and they were mounted on copper stubs with 187 
double-sided adhesive carbon tape and gold coated. The images were captured by using an 188 
acceleration voltage of 15kV at 1,500 magnification. 189 
 190 
2.5.2. Thermogravimetric analysis 191 
 192 
To evaluate the thermal stability of the samples, both powders and pure compounds, a 193 
thermogravimetric analysis (TGA) (StareSystem, Mettler Toledo Inc., Switzerland) was 194 
performed. The TGA was carried out from 50°C to 600°C at a heating rate of 10°C/min under a 195 
nitrogen atmosphere (20 mL/min). Sample weight versus temperature curves were recorded 196 
using the STARe software of (Version 9.01, Mettler Toledo) in triplicate. The samples were 197 
previously conditioned in a desiccator with P2O5 until constant weight. 198 
 199 
2.5.3. Concentration of eugenol in the powders and encapsulation efficiency 200 
 201 
Spectrophotometric analysis was used to analyze the concentration of encapsulated eugenol in 202 
the dried formulations, previously submitted to methanol extraction. 0.1 g of sample were 203 
weighed using an analytical balance (ME36S, Sartorius,Germany; ±0.00001 g) and extracted in 204 
100 mL of methanol under constant stirring for 24h (previously determined maximum time of 205 
extraction). Then, the absorbance of the filtered samples was measured in triplicate, by using a 206 
spectrophotometer (ThermoScientific spectrophotometer Evolution 201 UV–vis) at 282 nm 207 
(maximum eugenol absorption in methanol). The extract of the corresponding control without 208 
eugenol was used as a blank in each case. The calibration curve (y=0.018·x; R2=0.998) was 209 
obtained from the absorbance measurements of standard solutions of eugenol and was used to 210 
determine the concentration of eugenol in the samples.  211 
The encapsulation efficiency (%EE) was calculated by using Equation 1, where CE was the amount 212 





· 100       Equation 1 215 
 216 
2.5.4. Extraction and quantification of the lipid content in the whole particles and on their 217 
surface. 218 
 219 
The surface and total lipids were extracted using the methodology described by Damerau et al. 220 
(2014). First, samples (0.3 g) were washed with 5 mL of heptane by means of a mild shaking in 221 
an orbital shaker for 15 min and then centrifuged at 2,000 rpm for 2 min. For the extraction of 222 
total lipids, 0.3 g of sample were re-suspended in 3 mL of water at 40°C and vortexed. The lipids 223 
were extracted by shaking in an orbital shaker for 15 min using 10 mL of a heptane/2-propanal 224 
mixture (3:1, v/v). After shaking, the mixture was centrifuged at 3000 rpm for 2 min and the 225 
organic phase was collected. 226 
The fatty acid composition of the lipid extracts (both surface and total lipids) was analysed by 227 
using the method described by Damerau et al. (2014). This method is based on the saponification 228 
of the sample, followed by the methylation of the liberated fatty acids in the presence of boron 229 
trifluoride. All samples were analyzed by using a Hewlett Packard 5890 Series II GC (Karls-ruhe, 230 
Germany) equipped with an automated on-column injection system and a flame ionization 231 
detector (FID). The conditions were as follows: column, 60 m × 0.32 mm i.d., 0.10 µm, Rtx-5 w/ 232 
Integra Guard (crossbond 5% diphenyl-95% dimethyl polysiloxane) capillary column (from 233 
Restek); carrier gas, helium (>99.996%) at a constant flow of 1.4 mL/min; temperature program, 234 
70 °C (1 min), 60 °C/min to 245 °C (1 min), 3 °C/min to 275 °C (32 min); detector temperature, 235 
300 °C. The fatty acid methyl esters were identified through the retention times by comparison 236 
to a standard GLC-63 mixture of fatty acid methyl esters and quantified through the peaks’ areas 237 
by means of the internal standard method, (C19:0 methyl ester as the internal standard). The 238 
content of each fatty acid was determined, and referred per g of solid powder, and the total 239 
lipid content was estimated from the total sum of all fatty acids. 240 
 241 
2.6. Release Kinetics of eugenol from powders into food simulants 242 
 243 
Four different food simulants were used for the release studies: 3% (w/v) acetic acid (B); 10% 244 
(v/v) (A), 20% (v/v) (C) and 50% (v/v) (D1) ethanoic solutions. 0.1 g of each sample was placed 245 
into flasks containing 100 mL of each simulant. Release studies were carried out throughout 90 246 
minutes at 25°C, using a spectrophotometric method, at 282 nm of wavelength (where the 247 
eugenol absorbance is maximum), to determine the released E  at different times (1, 3, 5, 7, 10, 248 
15, 20, 30 and 90 minutes). The assay was performed in triplicate. The results were expressed 249 
as the amount of eugenol per gram of dried powder (mg /g powder). The amount of eugenol 250 
released at each time (Mt) was fitted to Peleg’s model (Peleg, 1988), described by Equation 2, 251 
and parameters k1 (inverse of the initial release rate) and k2 (inverse of the asymptotic value) 252 
were obtained. The delivered amount at equilibrium (M∞) was deduced from k2 (Equation 3). M0 253 














        Equation 3 258 
 259 
2.7. Antioxidant activity 260 
 261 
The antioxidant capacity of the powders was determined by using a 2,2-Diphenyl-1-pikryl-262 
hydrazyl (DPPH) reduction method, following the methodology described by Brand-Williams, 263 
Cuvelier & Berset (1995). In this method, the stable free radical, DPPH˙, which absorbs at 515 264 
nm, disappears after accepting an electron or hydrogen radical from the antioxidant 265 
compounds. For this purpose, 0.1 g of powder was dispersed in 100 mL of methanol under 266 
stirring for 30 minutes. Different volumes of the dispersions were reacted with a 0.06 mM 267 
methanol solution of DPPH˙. The absorbance measurements were taken in triplicate at 25°C 268 
after 2 hours, when the reaction (absorbance at 515 nm) reached a plateau by using a 269 
spectrophotometer (Thermo-Scientific spectrophotometer Evolution 201 UV-visible). The DPPH˙ 270 
concentration (mM) in the reaction medium was determined from the calibration curve 271 
(Equation 4) determined by linear regression (R2 = 0.997). The reduction percentage in DPPH˙ 272 
concentration (%DPPH˙rem) was calculated using Equation 5. 273 
        274 
𝐴𝑏𝑠515𝑛𝑚 = 11.793 · [𝐷𝑃𝑃𝐻

















DPPH       Equation 5 277 
 278 
where, [DPPH˙]t=2h is the concentration of DPPH˙ at the equilibrium time and [DPPH˙]t=0 is the 279 
initial concentration. From these values, the parameter EC50 (the antioxidant concentration 280 
required to reduce the initial [DPPH] concentration to 50%: efficient concentration) was 281 
determined through the relationship between the % [DPPH˙]rem and the mass ratio of powder to 282 
DPPH˙ (mg powder/mg DPPH). Thus, a low value of EC50 is related to a higher antioxidant activity 283 
of the analysed sample. The antioxidant activity of the pure eugenol was also determined, using 284 
the same method. 285 
 286 
2.8. Antimicrobial activity 287 
 288 
The antimicrobial effectiveness of powders was evaluated by using an in vitro method adapted 289 
from Cano, Cháfer, Chiralt & González-Martínez (2015). Two bacteria, Listeria innocua as Gram+ 290 
and Escherichia coli as Gram-, were used. The bacteria were regenerated by transferring a 291 
loopful into 10 mL of TSB and incubating at 37°C overnight. A 10 µL aliquot from the overnight 292 
culture was again transferred to 10 mL of tryptic soy broth (TSB) and grown at 37°C to the end 293 
of the exponential growth phase. These cultures were diluted to approximately 5.0–6.0 log 294 
CFU/mL. Different amounts of each powder were added to test tubes containing 9 mL of TSB 295 
and 1 mL of the inoculum; the final E concentration (from the powder) ranged from 0.5 to 1.75 296 
g Eugenol/L. The mixtures were vortexed and kept under stirring for 30 min at the optimum 297 
growth temperature. A bacterial suspension sample of 1 mL was serially diluted in water 298 
peptone and 1 mL of the dilutions were inoculated into Petri dishes in duplicate by using Violet 299 
Red Bilis agar (Sharlab S.A., Barcelona, Spain) in the case of E. coli cultures, and Palcam Agar 300 
Base (Sharlab S.A., Barcelona, Spain) supplemented with Palcam Selective Supplement (Sharlab 301 
S.A., Barcelona, Spain) in the case of L. innocua. Plate samples were incubated for 24 or 48 h at 302 
37 °C for Listeria or E. coli, respectively, and then counted as CFU/mL.  303 
 304 
2.9. Statistical analysis 305 
 306 
Statgraphics Centurion XVI software (Manugistics Corp., Rockville, Md.) for Windows 5.1 307 
(Manugistic Corp. Rockville, MD, USA) was used to carry out a statistical analysis of data through 308 
an analysis of variance (ANOVA). Fisher´s least significance difference (LSD) was used at the 95% 309 
confidence level.  310 
 311 
 312 
3. Results and discussion 313 
 314 
3.1. Emulsion characterization 315 
 316 
The particle size distribution of the different formulations can be observed in Figure 1. All 317 
dispersions exhibited multimodal distributions with droplet diameters ranging from 0.1 to 100 318 
µm, except the EOA-WP formulation, which exhibited monomodal behaviour. The E-WP based 319 
emulsion had particle size distributions between 0.5 and 100 µm, with the main peak at 10 µm. 320 
Similar particles sizes have been found by other authors using whey protein-oil-water emulsions 321 
homogenized at similar homogenization pressures (100 MPa) (Hebishy, Zamora, Buffa, Blasco-322 
Moreno & Trujillo, 2017). However, the E-LE based emulsion showed the formation of smaller 323 
particles (main peak around 0.1 µm), which indicates the formation of lecithin nanoliposomes, 324 
although some bigger particles appeared at around 100 µm, which may be due to the formation 325 
of either some lamellar forms or some clusters of maltodextrins as a result of their high 326 
concentration in the emulsion. In fact, Gibis, Thellmann, Thongkaew & Weis (2014) obtained 327 
monomodal distributions (0.1 µm peak) using lecithin and different plant extracts submitted to 328 
higher homogenization pressures (155 MPa). The incorporation of oleic acid notably reduced 329 
(p<0.05) the particle sizes and promoted narrower particle size distributions in systems with WP, 330 
although the curve shifted to higher size values in the LE liposome systems, probably due to the 331 
OA interactions with the lipid associations of lecithin, which modify the aggregation number of 332 
the lipid association structure. The amphiphilic nature of OA favours the emulsification process 333 
and the reduction in the droplet particle size, as previously reported by other authors (Vargas, 334 
Albors, Chiralt & González-Martínez, 2009), but the OA interactions with other polar lipids, such 335 
as lecithin compounds, affect the final lipid rearrangement both on the lipid-water interface or 336 
in the lipid association of micellar structures.  OA interactions with WP can also imply differences 337 
in the amphiphilic layer adsorbed on the lipid (E) droplets, even provoking the displacement of 338 
protein from the interface due to the lower surface tension of the surfactant.    339 
The incorporation of CH to WP or LE systems provoked particle flocculation, especially in the WP 340 
systems, as revealed by the shift of the particle sizes towards multimodal distributions with 341 
bigger particles (peaks near 100 m, in both WP and LE systems). This effect could be due to the 342 
emulsion depletion associated with the exclusion effect (McClements, 2005). However, the 343 
positive charge of the polymer could also provoke an entanglement effect on the negatively 344 
charged droplets revealed by their zeta potential (Table S2). In lecithin-based formulations, 345 
attractive interactions between the positively-charged chitosan and the negatively-charged 346 
groups of phospholipids (pKa values of anionic phosphatidic groups are typically around 1.5; 347 
Ogawa, Decker & McClements et al., 2004), at an emulsion pH of nearly 4 (Table S2), were 348 
expected, leading to the formation of larger particles.  In fact, the zeta potential (Table S2) of 349 
CH-free EOA-LE system was -45.7 mV at the emulsion natural pH (Table S2), as reported by Gibis, 350 
Vogt & Weiss (2012) at pH 3.8. This charge was inverted when CH was incorporated, leading to 351 
a zeta potential of +61.5 mV.  352 
In WP systems, electrostatic interactions between whey protein and chitosan were not 353 
expected, since the isoelectric point (IP) of whey protein is around 4-5 (Giese, 1994) and, 354 
although the zeta potential of the WP emulsions at their natural pH (nearly 6) was negative, the 355 
incorporation of a CH solution decreased the pH to about 4 and the zeta potential became 356 
positive. The CH-free WP systems also exhibited positive zeta potential at this pH (4) as shown 357 
in Table S2, according to the IP of the protein. Moreover, at pH values close to the WP isoelectric 358 
point, the solubility of protein is limited which can lead to emulsion flocculation by solvent effect 359 
(McClements, 2005). Therefore, the use of chitosan promoted a greater polydispersity in the 360 
particle size distributions and the formation of bigger particles, associated with different 361 
aggregation phenomena, especially in WP-based dispersions. Light microscopy images in Figure 362 
1 show the different droplet sizes in the emulsions, coherent with the distributions commented 363 
on above. The flocculated particles and large lipid droplets can be clearly observed, reflecting 364 
the occurrence of coalescence, associated with the emulsion destabilisation provoked by CH 365 
addition in both WP and LE systems. 366 
All emulsions exhibited pseudoplastic rheological behaviour. Table S2 also shows the values of 367 
the rheological parameters (flow index: n and consistency index: K) and the apparent viscosity 368 
of the different emulsions at 50 s-1. All CH-free dispersions almost presented Newtonian 369 
behaviour (n close to 1), whereas the incorporation of CH promoted a more pseudoplastic 370 
pattern. The incorporation of OA did not produce significant changes in the rheological 371 
behaviour or viscosity of the dispersions (Table S2) (p>0.05). An increase in the emulsion 372 
consistency could be expected in line with the higher volume fraction of the dispersed phase, 373 
but the reduction in the particle size promoted by OA or its efficient incorporation into WP 374 
micelles or LE-liposomes could mitigate this effect. The dispersions turned more shear-thinning 375 
and viscous with the addition of CH, in agreement with the formation of large aggregates whose 376 
coarse structure would be more sensitive (e.g. disaggregation or deformation of large droplets) 377 
to the shear rate. 378 
 379 
3.2. Powder encapsulate characterization 380 
 381 
The morphology of the particles obtained by spray-drying depends on several factors, such as 382 
the drying kinetics and the liquid phase composition. At the beginning of the drying process, the 383 
surface of the atomized droplets begins to dry, forming a crust, then bubble nucleation occurs, 384 
and bubbles grow, enlarge and burst out through the surface until most of the internal moisture 385 
has evaporated (Rosenberg, Kopelman & Talmon, 1990). Since the drying conditions were 386 
constant for every formulation, the different morphology observed for dried particles (Figure 2) 387 
would only be affected by their composition. Factors, such as the film-forming properties of the 388 
drying carrier and the interactions of the wall material with the active substance (eugenol), could 389 
affect the morphology of the solid particles. Eugenol encapsulated in LE or WP (no OA or CH 390 
present) produced particles with irregular surfaces over a wide range of sizes, which is typical of 391 
low-loaded capsules. Surface irregularities suggest the swelling of the rubbery particle surface 392 
in the initial drying stages due to the internal pressure of the water vapour, which collapses 393 
when the internal vapour pressure decreases as a result of the lower volume of the internal lipid. 394 
Ré (1998) associated these particle shapes with a slow surface film formation during drying in 395 
the atomized droplet. Similar morphological characteristics were found by Carneiro, Tonon, 396 
Grosso & Hubinger (2013). In contrast, when the formulations contained OA as eugenol carrier, 397 
the particles became more spherical in shape with fewer surface irregularities, due to the 398 
presence of OA inside the particles (0.134 mass fraction in the powder, against 0.06 of E), which 399 
limits the further shrinkage of the non-lipid shell. As expected, bigger particles and large 400 
agglomerates were observed in systems containing chitosan. No notable differences in the 401 
particle appearance were observed when using LE or WP as wall materials, although in the WP 402 
systems a slightly higher degree of particle aggregation could be appreciated in the powder, thus 403 
indicating greater attractive forces between dry particles.  404 
The particle size distributions of the different powder formulations can be observed in Figure 2. 405 
As can be observed, all chitosan-free formulations exhibited very similar, “almost” monomodal, 406 
distributions with a mean particle diameter of around 15 µm, regardless of the wall material 407 
(WP or LE). A very small shoulder, corresponding to the finest particles (around 0.5 µm), was 408 
also observed in both systems. This is particularly interesting in the case of powders, as the 409 
population of smaller particles can penetrate the spaces between the larger ones, thus giving 410 
rise to powders with higher apparent density during the powder compaction (Carneiro et al., 411 
2013).  412 
The addition of chitosan shifted the particle size distributions towards larger sizes, exhibiting a 413 
multimodal pattern, as was also observed in SEM micrographs. Two main populations, showing 414 
peak values of 20 and 170 µm for EOA-WPCH and of 30 and 150 µm for EOA-LECH formulations, 415 
were observed. The high viscosity and larger particles of these emulsions could limit the jet 416 
disruption in smaller droplets during the spray drying process. Several authors (Augustin & 417 
Hemar, 2009; Bae & Lee, 2008; Carneiro et al., 2013; McClements, 2005) reported that the 418 
atomized droplet size depends directly on the emulsion viscosity at a constant atomization 419 
speed. The greater the emulsion viscosity, the larger the droplets formed during atomization, 420 
and consequently, the larger the particles in the obtained powder. 421 
Table S3 shows the moisture content and onset and peak temperatures from the TGA analysis 422 
of powder encapsulates. The different formulations exhibited moisture contents ranging 423 
between 1.7 to 3 g water/100 g dry powder.  424 
The TGA and DTGA curves of the different samples are shown in Figure 3. Two different weight 425 
loss steps were observed below 250oC. The first one, below about 100 ᵒC, must be attributed to 426 
the evaporation of the powder water content (He, Hong, Gu, Liu, Cheng & Li, 2016), while the 427 
small peaks (shoulders) in DGTA curves, at about 200-250 ᵒC, reflect the evaporation of eugenol 428 
(254oC boiling point) from the powder. The main thermodegradation step corresponds to the 429 
thermal degradation of the major compounds in the matrix (maltodextrins: 0.8-0.9 mass fraction 430 
in the powder), affected by their interactions with the other minor, non-volatile components 431 
(WP, LE, OA or CH). In Figure 3, the thermal degradation behaviour of pure components was also 432 
shown to facilitate the analysis of the component interaction effect on the thermal degradation 433 
of the different encapsulates. In the case of maltodextrins, the peak temperature of the 434 
maximum degradation rate is at 286 ᵒC, whereas in the powder encapsulates, these 435 
temperatures were about 283 and 260 ᵒC, for matrices containing WP and LE, respectively.. No 436 
practical effect of WP was observed on the thermal behaviour of maltodextrin matrices, 437 
whereas LE notably decreased the thermal stability of the powder. The WP powders degraded 438 
at a higher temperature than the LE, due to the proteins contribution to the increase in the 439 
mean molecular weight of the maltodextrin matrix and the subsequent enhancement of the 440 
cohesive forces through the entanglement effect of the protein chains. In contrast, the LE lipids 441 
reduce the thermal stability of the matrix, probably due to the plasticizing effect of the lipids, 442 
which reduce the attractive forces between the carbohydrate chains, weakening the network 443 
cohesion. OA or CH slightly affected the thermal degradation temperature of the WP powders, 444 
but the only significance is to be found in the small decrease provoked by OA, which could also 445 
be associated with its plasticizing effect in the matrix (Fabra, Talens & Chiralt, 2010). In the LE 446 
based systems, the CH or OA incorporation did not have a significant effect on the thermal 447 
stability of the material.  448 
As regards the loss of eugenol from the encapsulant matrix, associated to its thermal release, 449 
the behaviour of the powders was remarkably different. A clear peak (maximum evaporation 450 
rate) was observed at about 200 oC for samples containing CH, whereas the compound thermal 451 
release appeared at about 240 oC in WP systems with and without OA (respective shoulders in 452 
DGTA curves). In LE powders, the E thermal release overlapped with the degradation 453 
temperature range of the matrix and no specific E weight loss event was observed in the DGTA. 454 
In contrast, for free eugenol submitted to the same thermal test, the maximum evaporation rate 455 
occurred at 175 oC. These results reflect the different protective effect of the encapsulates when 456 
it is a matter of limiting the loss of E from the powder, the LE systems without CH being the most 457 
effective at retaining E in the matrix. The incorporation of CH into the encapsulates implied less 458 
protection against the evaporation of E, which suggests a poor inclusion of the compound in the 459 
particle core, but probably a greater presence on the particle surface. Additionally, the thermal 460 
stability of the encapsulated materials allows for their incorporation into different products 461 
submitted to thermal processing, involving temperatures lower than 175 oC or 200 oC, for 462 
powders with or without CH, preventing the potential thermal release of eugenol, as previously 463 
observed by other authors (He et al., 2016). 464 
In order to know the encapsulation efficiency (EE) of eugenol, its total content in each powder 465 
sample was determined and compared with the theoretical incorporated amount (Table S1). 466 
Table 1 shows the different EE values for each sample. EE was very high (around 94-99%) when 467 
using only WP or LE as wall materials. These values were higher than those found by other 468 
authors encapsulating eugenol with solid lipid nanoparticles (SLN) (Cortes-Rojas et al., 2014), 469 
and similar to those found by Seo, Min & Choi (2010) using -cyclodextrin. The incorporation of 470 
OA into the emulsions slightly decreased the EE values, only being significant in the EOA-WP 471 
samples. On the other hand, the use of chitosan remarkably reduced (p<0.05) the EE values to 472 
22 and 46% for WP and LE systems, respectively. The presence of free OA containing eugenol on 473 
the surface of the dried particles (Table 1) could explain the lower EE values, especially in the 474 
samples containing CH. To verify this hypothesis, the total and surface lipid contents were 475 
analysed, as described in section 2.5, through the analyses of fatty acids present in the whole 476 
particles (total lipid content: TLC) and on their surface (surface lipid content: SLC). 477 
Table S4 shows the TLC and SLC, and the specific content of the different fatty acids found in 478 
each spray-dried particle. Particles from LE systems contained a higher fat content and different 479 
fatty acid profiles (both in TLC and SLC) than those from WP systems, in line with the lecithin 480 
composition. As expected, the TLC values were always higher than the SLC, indicating the 481 
predominant location of lipids in the internal core of the particles, with a partial retention at 482 
surface level. WP based samples without OA had a very low lipid content, coming from the raw 483 
WP powder, and about 40 % were on the particle surface. In the rest of the samples, the TLC 484 
quantified through the total fatty acids was, as expected, lower than the theoretical lipid load in 485 
the powders (OA and/or LE), although in samples containing OA the values were very close, since 486 
this component was present at a higher ratio than LE (Table S1). However, the percentage of the 487 
SLC with respect to TLC greatly differed from powder to powder. Whereas only 4.5 and 3.5 % 488 
was present on the particle surfaces of OA loaded WP and LE systems, respectively, powders 489 
with CH contained 65 and 54 % of the total lipids on the particle surface, in WP and LE systems, 490 
respectively. These results indicate that most of the lipids carrying eugenol were entrapped in 491 
the internal core of the dried particles, except when CH was incorporated into the emulsions, 492 
where a very high ratio of lipids was present on the particle surface. This could be attributed to 493 
the greater instability of the flocculated emulsions, which promotes the oil droplet coalescence 494 
during the spray drying process, reaching larger sizes than the atomized droplets. In this context, 495 
the lipid phase was not efficiently entrapped in the core of the dried particles, but 496 
extended/adsorbed on their surface, also carrying eugenol to the particle surface, from which it 497 
could easily evaporate. This behavior explains the much lower EE values for eugenol in powders 498 
containing CH.   499 
Figure S1 shows the profile of major fatty acids (individual content with respect to the total 500 
content) in the whole particles and on their surface, compared with the typical profile of the raw 501 
OA component. Powders with OA (EOA-WP, EOA-LE, EOA-WPCH and EOA-LECH) exhibited a very 502 
similar profile at internal and surface levels. This was also very close to that of the raw OA, due 503 
to its higher mass fraction in the powder. This suggests that there was no notable amount of the 504 
LE lipids present on the particle surface and most of the formed liposomes were entrapped in 505 
the particle core, carrying most of the incorporated eugenol. In samples without OA, significant 506 
differences were observed in the fatty acid profiles of the particle surfaces and whole particles, 507 
according to the specific surface adsorption capacity of the different lipids of raw LE or WP 508 
products. This was particularly notable in OA-free LE samples, where LE lipid fractions containing 509 
more OA were predominantly adsorbed on the particle surface. 510 
It can be assumed that the eugenol carried by the surface lipids quickly evaporates, mainly 511 
during the spray drying process, due to the lack of a true encapsulation, decreasing the total 512 
content in the powder or the EE. Taking into account the SLC values, and considering that most 513 
of the surface lipids come from the incorporated OA component, the loss of eugenol during the 514 
drying process was estimated from the E:OA ratio in the emulsions. In this sense, around 4 and 515 
3% of the incorporated eugenol would be present on the particle surface in EOA-WP and EOA-516 
LE samples, respectively, whereas 60 and 50% of the incorporated E would be on the particle 517 
surface in EOA-WPCH and EOA-LECH formulations. The sum of the encapsulated and surface 518 
eugenol was nearly 100 % of the incorporated E in every case, which verifies the hypothesis that 519 
only when lipids carrying E exhibited small droplet size in the initial emulsions, was the EE high 520 
and a great amount of the compound could be retained in the powder. Therefore, all the factors 521 
contributing to a reduction in droplet size and emulsion stability will favour the EE in the spray 522 
drying processes. The less efficient retention of E in powders containing CH during its thermal 523 
release, deduced from the TGA analyses, is also coherent with the higher degree of instability of 524 
the emulsions containing CH.   525 
 526 
3.3. Release Kinetics 527 
As concerns the release kinetics of the encapsulated E from the different formulations into food 528 
simulants of differing polarity, Figure 4 shows the percentage of eugenol released (% Mt/M0, 529 
where Mt is the amount of eugenol released at each time and M0 is the initial eugenol content) 530 
as a function of time for LE powders. Very similar behaviour was observed for WP-based 531 
formulations (data not shown). The experimental data (points) and curves predicted (lines) by 532 
the fitted Peleg model are shown. Table S5 shows the parameters of the Peleg model, where k1 533 
is the kinetic constant of the model (min/(mg E/g powder)) related to the mass transfer rate at 534 
the beginning of the process and k2 is related to the asymptotic value of the curve or amount 535 
released at equilibrium (1/k2=M∞, mg eugenol/g powder). The maximum release ratio (M∞/M0) 536 
was estimated with respect to the total methanol extracted eugenol (M0) in each powder. A 537 
good fit of the model was obtained in every case, as reflected by the R2 values in Table S5. 538 
All powders released practically their total content of E at equilibrium (M∞) (M∞/M0 ranged 539 
between 84-100%) in the tested aqueous simulants, as shown in Table S5. This suggests that the 540 
release of the active agent was not notably affected by pH or polarity of the food simulant. No 541 
significant differences in the M∞/M0 values were found (p>0.05) due to the use of different 542 
simulants or wall materials. As concerns the eugenol release rate (inverse of K1), no significant 543 
effect of the wall material (WP or LE) (p>0.05) was observed, but the release rate significantly 544 
decreased when incorporating OA and CH, obtaining the slowest rates in formulations 545 
containing chitosan (greatest k1 values). This CH effect could be attributed to the lower content 546 
of encapsulated eugenol in these formulations, which implies a minor driving force for the 547 
release. In general, the different simulants were found to have no significant effect on the K1 548 
values of a determined sample, exhibiting a burst eugenol release throughout the first 20 min. 549 
The behaviour observed is coherent with the high water affinity/solubility of the shell material, 550 
which favours the fast disruption of the capsules with the subsequent release of the E content. 551 
 552 
3.4. Antioxidant and antibacterial activity 553 
All powders exhibited antioxidant and antimicrobial activities to some extent, depending on the 554 
eugenol content in each sample. The antioxidant activity was evaluated in terms of EC50 values. 555 
This parameter indicates the amount of sample needed to halve the DPPH radical amount. Thus, 556 
the lower the EC50 values, the greater the antioxidant activity. In Table 1, the EC50 values of the 557 
different formulations, together with the pure eugenol, are shown. Pure eugenol showed the 558 
lowest EC50 value, 0.22 mol eugenol/mol DPPH, which was similar to that previously reported by 559 
Brand-Williams et al. (2005). The EC50 values of CH-free powders (expressed in terms of moles 560 
of eugenol in the powder per mol DPPH) were in the range of the pure component. These results 561 
reflected the fact that the antioxidant activity of eugenol was efficiently preserved during the 562 
drying process when using lecithin or whey protein as wall materials, with or without OA as 563 
carrier agent. However, powders with CH exhibited higher EC50 values (lower antioxidant 564 
activity), referred to their E content, which could be due to the partial oxidation of the 565 
compound retained in the external zone of the particles (surface lipids). 566 
The antimicrobial activity of the samples was evaluated against one Gram – bacterium (E. coli) 567 
and one Gram + (L. innocua). Powders with CH did not exhibit antibacterial effect at any 568 
concentration tested, which may be explained by their low eugenol content, which did not 569 
exceed the MIC of either bacterium in any case. In Figure 5, the bacterial growth inhibition of 570 
the CH-free powders as a function of the powder concentration (mg powder/mL) can be 571 
observed. No significant differences were found between WP and LE systems and, therefore, 572 
the mean values for a determined powder concentration are shown in Figure 5 for powders with 573 
and without OA. As expected, the CH-free samples exhibited a dose-dependent antimicrobial 574 
activity against both bacteria. Formulations were more effective against E. coli than against L. 575 
innocua, in agreement with that previously reported by Gaysinsky, Davidson, Bruce & Weiss 576 
(2005) for eugenol encapsulated in surfactant micelles. 577 
In the case of E. coli, OA-free powders exhibited the most marked antibacterial effect, due to 578 
their greater eugenol load (Table 1). A complete growth inhibition (bactericidal effect) was 579 
obtained with 15 mg /mL, which corresponds to 1 g eugenol/L. This value agrees with the MIC 580 
found by other authors (Kamatou et al., 2012; Shah, Davidson & Zhong, 2013) for E. coli (around 581 
1-1.6 g eugenol/L). The incorporation of OA into formulations significantly decreased the 582 
antibacterial action, only provoking nearly a 3 Log CFU reduction when using 30 mg powder/mL. 583 
As concerns L. innocua, both powders (with and without OA) had a similar antibacterial effect, 584 
despite the different eugenol content, causing a total inhibition at about 25 mg powder/mL 585 
(equivalent to about 1.2 or 1.6 g eugenol/L, respectively for powder with and without OA). This 586 
could be attributed to the antimicrobial activity reported for some unsaturated fatty acids (such 587 




The encapsulation efficiency (EE) of eugenol in spray-dried powders containing whey protein or 592 
lecithin as wall materials and maltodextrin as drying coadjuvant was very high (95-98 %), while 593 
the incorporation of oleic acid (OA) as eugenol carrier or chitosan (CH) to the liquid formulations 594 
did not improve EE. CH provoked emulsion destabilization, which had a very negative effect on 595 
the EE. All encapsulating powders exhibited antioxidant activity, coherent with their respective 596 
eugenol content, in line with the fast, complete release of eugenol in aqueous systems. The 597 
antibacterial effect of the powders against E. coli was also coherent with their eugenol content, 598 
but an additional positive effect of OA was detected in the powder antilisterial action. All 599 
encapsulating powders presented small particles and a high affinity /solubility in aqueous 600 
systems of differing polarity and pH, which allows for a relatively fast, total release of the active 601 
compound. The thermal release of eugenol was also inhibited in the powders (mainly in those 602 
which were CH-free), which would allow for their use in dry thermal processes, such as the 603 
preparation of an active master batch of thermoplastic polymers. Their incorporation as an 604 
ingredient or in separate sachets in foodstuffs would permit them to be better preserved against 605 
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Figure 1. Typical particle size distributions of eugenol (E) emulsions using whey protein (A) or lecithin (B) 716 
as wall materials, incorporating or not oleic acid (OA) and chitosan (CH) ( E; EOA; EOA-CH). 717 
Light microscopy images (x40) of the different emulsions are also shown. 718 
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 721 
Figure 2. Typical particle size distributions of powders prepared using whey protein (A) and lecithin (B) 722 
as wall materials, incorporating or not oleic acid and chitosan (  E;  EOA;  EOA-CH). SEM 723 
micrographs of the different encapsulated eugenol particles (x1500) are also shown. 724 

























































Figure 3. Weight loss curves (A and C) and derivative curves (B and D) from TGA analysis from 25ᵒC to 728 
600ᵒC of encapsulated samples (A and B) and different pure components (C and D). 729 
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Figure 4. Percentage of eugenol released at each time (Mt/M0) from lecithin-based powders in four 734 
different aqueous food simulants: 3% acetic acid, 10% ethanol, 20% ethanol and 50% ethanol. 735 
Experimental data (  E-LE;  EOA-LE;  EOA-LECH) and values predicted by Peleg’s model (  E-LE; 736 
 EOA-LE; EOA-LECH). 737 


























































Figure 5. Antimicrobial activity of encapsulated eugenol particles (  E;  EOA; × Control) against 740 
E. coli and L. innocua. Mean values and 95% LSD intervals. 741 







































Figure S1. Profile of major fatty acids (individual content with respect to the total content) found in the 745 
different sample formulations, in the total extracted lipid fraction (black) and in the lipid extracted from 746 
the capsule surface (grey).  White bars correspond to the profile of fatty acids in the incorporated oleic 747 
acid.  748 































































Lauric Palmitic Stearic Oleic Linoleic
EOA-LECH
Table 1. Theoretical and extractable eugenol content (mg/g dried powder), encapsulation efficiency and 750 
eugenol content on the particle surface (SLC) of different encapsulates. Antioxidant activity in terms of 751 
EC50 values of particles encapsulating eugenol was also shown referred per mass unit of powder and mass 752 
unit of the encapsulated eugenol. Mean values and (standard deviation). 753 
 754 
abcd Different letters in the same column indicate significant differences among formulations (p<0.05). 755 
(1) Estimated from surface lipid content values (SLC) and nominal E:OA ratio  in the powders 756 
(2) Percentage of the incorporated eugenol not encapsulated in the samples, deduced from the SLC and 757 
E:OA ratio in the powders. 758 













EC50 (mg powder 
/mg DPPH) 
EC50 (mg eugenol/ 
mg DPPH) 
E-WP 65.22 62 (2) 95 (3)d - - 1.64 (0.05)a 0.107 (0.003)a 
EOA-WP 56.60 49 (3) 87 (5)c 2.3 (0.6)a 4.13 (1.14)a 2.12 (0.15)a 0.120 (0.008)a 
EOA-WPCH 56.43 12.6 (1.7) 22 (3)a 34.0 (1.4)c 60 (3)c 7.8 (0.9)c 0.44 (0.05)c 
E-LE 65.22 64 (4) 98 (6)d - - 1.78 (0.14)a 0.116 (0.009)a 
EOA-LE 56.60 53 (3) 95 (5)d 1.9 (0.5)a 3.31 (0.02)a 1.709 (0.015)a 0.1114 (0.0010)a 
EOA-LECH 56.43 26.2 (1.9) 46 (3)b 28.0 (0.4)b 49.6 (0.08)b 4.6 (0.3)b 0.260 (0.019)b 
Pure E       0.092 (0.002)a 
Table S1. Mass fraction of each component (g/g total solids) and % total solids of the different 760 
formulations.  761 
Formulation WP* LE* MD* Eugenol OA* CH* % Total solids 
E-WP 0.022 - 0.913 0.065 - - 43 
EOA-WP 0.019 - 0.792 0.057 0.132 - 56 
EOA-WPCH 0.019 - 0.790 0.056 0.132 0.003 56.16 
E-LE - 0.022 0.913 0.065 - - 43  
EOA-LE - 0.019 0.792 0.057 0.132 - 56 
EOA-LECH - 0.019 0.790 0.056 0.132 0.003 56.16 
* WP: Whey Protein Isolate; LE: Lecithin; MD: Maltodextrin; OA: Oleic acid; CH: Chitosan 762 
  763 
Table S2. Zeta potential, pH, rheological parameters and apparent viscosity at 50 s-1 of the different 764 
emulsions. 765 
 766 
abcd Different letters in the same column indicate significant differences among formulations (p<0.05). 767 
*at the pH of the emulsion 768 






K (Pa·sn)·100 n η50 (mPa·s) 
E-WP 6.6 -28.9 (1.5)b +19. (0.4)a 5.81 (0.18)a 0.993 (0.004)cd 56.2 (1.9)a 
EOA-WP 5.7 -32.5 (0.9)a +12 (2)a 6.95 (0.15)a 0.995 (0.005)d 68.0 (1.3)ab 
EOA-WPCH 4.1 +40 (3)c +40 (3)b 41.65 (11.13)b 0.836 (0.018)b 219 (46)c 
E-LE 4.3 -46.6 (0.5)d - 73 (0.9)a 0.988 (0.005)cd 69 (8)ab 
EOA-LE 4.4 -45.7 (0.5)d - 90 (10)a 0.982 (0.004)c 84 (9)b 
EOA-LECH 4.0 +61.5 (0.9)e - 69 (17)c 0.726 (0.020)a 214 (11)c 
Table S3. Moisture content and thermal degradation temperatures (onset values, Tonset and value at 770 
maximum degradation rate, Tmax) of the particles using whey protein and lecithin as wall materials, 771 






abcd Different letters in the same column indicate significant differences among formulations (p<0.05). 778 
 779 
Formulation 
% MC (dry 
weight basis) 
Tmax (°C) Tonset (°C) 
E-WP 3.01 (0.02)d 283.7 (0.8)c 221.4 (0.7)ab 
EOA-WP 2.74 (0.09)c 282 (2)b 222 (2)ab 
EOA-WPCH 1.50 (0.06)b 284.2 (1.0)c 227 (13)b 
E-LE 2.84 (0.05)c 259,8 (0,6)a 214.8 (0,9)a 
EOA-LE 1.77 (0.03)a 258,6 (0,3)a 224.1 (1.6)ab 
EOA-LECH 2.97 (0.14)c 259,4 (0,3)a 226.4 (0.5)b 
Table S4. Lipid profile of the different formulations expressed as total (TLC) and superficial lipid content (SLC), in mg fatty acid/g powder. Total fatty acids is the sum of the 780 
different lipids in TLC and SLC. % SLC is the total amount of fatty acids present on the surface with respect to the total lipid content. Mean values (and standard deviation). 781 
* n.d.: Non-detected.782 
 E-WP EOA-WP EOA-WPCH E-LE EOA-LE EOA-LECH 
Fatty acids TLC SLC TLC SLC TLC SLC TLC SLC TLC SLC TLC SLC 
Lauric C12:0 n.d.* n.d. 1.95 (0.04) 0.046 (0.014) 1.79 (0.05) 1.18 (0.18) n.d. n.d. 1.8 (0.2) n.d. 1.5 (0.4) 0.869 (0.015) 
Miristic C14:0 n.d. n.d. 0.592 (0.014) 0.013 (0.018) 0.583 (0.095) 0.41 (0.03) n.d. n.d. 0.58 (0.05) n.d. 0.51 (0.08) 0.304 (0.004) 
Palmitic C16:0 n.d. 0.0130 (0.0004) 4.03 (0.10) 0.19 (0.04) 4.186 (0.07) 3.096 (0.108) 1.36 (0.12) 0.051 (0.005) 5.4 (0.5) 0.15 (0.03) 4.7 (0.2) 2.71 (0.03) 
Margaric C17:0 n.d. 0.0115 (0.0007) n.d. 0.0099 (0.0002) n.d. 0.032 (0.002) n.d. n.d. n.d. n.d. n.d. n.d. 
Estearic C18:0 0.0386 (0.0007) 0.0202 (0.0004) 2.214 (0.009) 0.1443 (0.0018) 2.290 (0.009) 1.81 (0.04) 0.317 (0.013) 0.044 (0.006) 2.56 (0.09) 0.1117 (0.0008) 2.325 (0.007) 1.251 (0.010) 
Oleic C18:1 (n9) 0.31 (0.02) 0.106 (0.002) 97.14 (1.09) 4.4 (1.2) 98.8 (1.3) 73 (3) 2.19 (0.09) 0.927 (0.014) 98 (4) 3.6 (0.6) 95 (3) 50.8 (0.8) 
Vaccenic C18:1 (n7) n.d. n.d. 0.57 (0.03) 0.031 (0.009) 0.3 (0.5) 0.009 (0.012) n.d. n.d. 0.5 (0.4) n.d. 0.680 (0.017) 0.079 (0.003) 
Linoleic C18:2 0.032 (0.004) 0.0067 (0.0007) 13.34 (0.24) 0.57 (0.18) 13.06 (0.14) 0.1171 (0.0004) 4.5 (0.4) 0.111 (0.004) 16.6 (1.0) 0.50 (0.09) 15.2 (1.4) 9.14 (0.16) 
Linolenic C18:3 n.d. n.d. n.d. n.d. n.d. n.d. 0.32 (0.04) n.d. 0.28 (0.03) n.d. 0.24 (0.02) 0.16571 (0.00009) 
Arachidic C20:0 n.d. n.d. 0.258 (0.002) n.d. 0.12 (0.17) n.d. n.d. n.d. 0.257 (0.013) n.d. n.d. n.d. 
Gondoic C20:1 n.d. n.d. 0.674 (0.010) n.d. 0.55 (0.03) n.d. n.d. n.d. 0.530 (0.015) n.d. 0.54 (0.03) n.d. 
Behenic C22:0 n.d. n.d. 0.108 (0.004) n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Lignoceric C24:0 n.d. n.d. 0.0917 (0.0010) n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. n.d. 
Total fatty acids 
(mg/g) 
0.38 (0.03) 0.157 (0.003) 121.0 (1.5) 5.5 (1.5) 121.7 (1.5) 79 (3) 8.6 (0.7) 1.13 (0.03) 127 (6) 4.4 (0.7) 121 (5) 65.36 (1.05) 
% SLC 40.85 4.51 65.10 13.11 3.45 54.08 
Table S5. Maximum eugenol release ratio (M∞/M0)* and parameters of Peleg´s model for the different 
encapsulated systems in the different food simulants: inverse of the initial release rate (k1) (min/(mg 
eugenol /g powder)) and equilibrium value, M∞ (1/k2) (mg eugenol/g powder). 
Formulation Parameters 
SIMULANTS 
Ethanol 10% Ethanol 20% Ethanol 50% AA 3% 
E-WP 
k1 0.0065 (0.0009)a,1 0.0053 (0.0010)a,1 0.039 (0.009)a,1 0.0041 (0.0019)a,1 
M∞=1/k2 60.3 (0.3)d,1 60.2 (0.8)d,1 68.5 (1.7)d,2 60.22 (1.06)d,1 
M∞/M0 (%) 97.1 (1.7)c,1 97.1 (1.3)c,1 100 (0)a,1 97.1 (1.7)bcd,1 
R2 ≥ 0.999 ≥ 0.999 ≥ 0.999 ≥ 0.999 
EOA-WP 
k1 0.0109 (0.0013)a,1 0.012870a,1 0.02888 (0.00102)a,1 0.018 (0.013)ab,1 
M∞=1/k2 47.4 (0.7)c,1 48.78 (0.15)c,1 56.6 (4.4)c,2 59 (5.3)c,2 
M∞/M0 (%) 89.4 (1.3)b,1 92.0 (0.3)b,1 100 (0)a,2 100 (0)c,2 
R2 ≥ 0.998 ≥ 0.998 ≥ 0.999 ≥ 0.998 
EOA-WPCH 
k1 0.06 (0.03)bc,1 0.09 (0.02)bc,1 0.159 (0.006)b,2 0.09 (0.03)c,1 
M∞=1/k2 10.38 (0.02)a,1 14.5 (0.3)a,12 18.6 (1.8)a,2 16.7 (0.3)a,2 
M∞/M0 (%) 74.16 (0.14)a,1 100 (0)c,2 100 (0)a,2 100 (0)cd,2 
R2 ≥ 0.958 ≥ 0.945 ≥ 0.925 ≥ 0.998 
E-LE 
k1 0.007 (0.005)a,1 0.0080 (0.0013)a,1 0.032 (0.008)a,1 0.009 (0.003)a,1 
M∞=1/k2 62.6 (3.1)d,12 61.7 (1.4)d,12 66.7 (6.8)d,2 58.6 (0.8)d,1 
M∞/M0 (%) 99.2 (1.4)c,1 97.8 (0.3)c,1 98,9 (2.0)a,1 96.1 (1.3)bc,1 
R2 ≥ 0.999 ≥ 0.998 ≥ 0.997 ≥ 0.998 
EOA-LE 
k1 0.030 (0.002)ab,1 0.032 (0.008)ab,1 0.03 (0.03)a,1 0.020 (0.006)ab,1 
M∞=1/k2 58.4 (0.7)d,2 56.7 (0.6)d,2 56.5 (4.6)c,2 51 (0.7)c,1 
M∞/M0 (%) 100 (0)c,2 99.4 (0.9)c,2 97 (5)a,2 89.4 (1.2)a,1 
R2 ≥ 0.997 ≥ 0.993 ≥ 0.958 ≥ 0.996 
EOA-LECH 
k1 0.095 (0.008)c,1 0.061 (0.014)c,1 0.042 (0.013)a,1 0.047 (0.011)b,1 
M∞=1/k2 26.3 (2.3)b,1 25.4 (0.8)b,1 31.8 (2.4)b,2 27.4 (1.3)b,12 
M∞/M0 (%) 91 (8)b,12 88 (3)a,1 100 (0)a,3 94.4 (4.4)b,2 
R2 ≥ 0.986 ≥ 0.999 ≥ 0.997 ≥ 0.994 
 
* related to the initial eugenol amount determined by methanol extraction. 
abcd Different letters in the same column indicate significant differences among formulations (p<0.05). 
1234 Different numbers in the same line indicate significant differences among food simulants (p<0.05). 
 
